← Back to patent-cliff list
AMXT-1501
Tier C — Watch / tradeAMXT-1501
Aminex Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：MYCN
Indications (approved)：Osteosarcoma, 横纹肌样瘤, 畸胎瘤, Diffuse intrinsic pontine glioma, Neuroblastoma, 生殖细胞和胚胎肿瘤, 尤因肉瘤, Melanoma
Regional status
US
Phase II
2022-11-29
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AMXT-1501?
Approved indications include: Osteosarcoma, 横纹肌样瘤, 畸胎瘤, Diffuse intrinsic pontine glioma, Neuroblastoma, 生殖细胞和胚胎肿瘤, 尤因肉瘤, Melanoma.
When does the AMXT-1501 patent expire?
No public expiry year is available for AMXT-1501 yet; this page updates once verified.
How do I get a quote for AMXT-1501 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21